Navigation Links
More evidence on benefits of high blood pressure drugs in diabetic eye disease
Date:2/24/2010

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say. The findings are in ACS' Journal of Proteome Research, a monthly publication.

Edward Feener and colleagues point out that diabetic retinopathy is a common complication of diabetes, which affects millions of people worldwide. It involves damage to blood vessels in the retina, the light sensitive tissue in the back of the eye. Previous studies suggested that drugs used to treat high blood pressure, including ACE inhibitors and angiotensin receptor blockers (ARBs), may help prevent the condition.

The scientists analyzed proteins from the retinas laboratory mice with normal blood pressure and diabetes and compared them to those of non-diabetic mice. They identified 65 abnormal proteins in the diabetic mice out of more than 1,700 proteins in the study. Treatment with the ARB medication, candesartan, prevented the abnormal changes in more than 70 percent of the proteins.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. Retail meat linked to urinary tract infections: Strong new evidence
2. First evidence that blueberry juice improves memory in older adults
3. Research adds to evidence that autism is a brain connectivity disorder
4. More evidence on benefits of high blood pressure drugs in diabetic eye disease
5. New evidence that dark chocolate helps ease emotional stress
6. Does green tea prevent cancer? Evidence continues to brew, but questions remain
7. Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history
8. Growing outcomes evidence spurs renewed interest in unique heart valve procedure
9. Researchers find first evidence of virus in malignant prostate cells
10. Growing evidence of marijuana smokes potential dangers
11. First direct evidence of substantial fish consumption by early modern humans in China
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More evidence on benefits of high blood pressure drugs in diabetic eye disease
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: